---
title: "Anika Therap | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 30.62 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277039084.md"
datetime: "2026-02-26T12:20:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277039084.md)
  - [en](https://longbridge.com/en/news/277039084.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277039084.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277039084.md) | [繁體中文](https://longbridge.com/zh-HK/news/277039084.md)


# Anika Therap | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 30.62 M

Revenue: As of FY2025 Q4, the actual value is USD 30.62 M, beating the estimate of USD 28.88 M.

EPS: As of FY2025 Q4, the actual value is USD 0.12, beating the estimate of USD -0.215.

#### Fourth Quarter 2025 Financial Summary

Anika Therapeutics, Inc. reported total revenue of $30.6 million for the fourth quarter of 2025, which remained flat compared to the fourth quarter of 2024. Commercial Channel revenue increased by 22% year over year to $13.3 million, while OEM Channel revenue decreased by 12% to $17.3 million. The gross margin expanded to 63%. Operating expenses were $18.5 million. GAAP income from continuing operations was $1.8 million, and adjusted net income from continuing operations was $4.6 million. Adjusted EBITDA stood at $4.5 million. As of December 31, 2025, cash and cash equivalents were $57.5 million.

#### Full Year 2025 Financial Summary

For the full year 2025, total revenue was $112.8 million, marking a 6% decrease compared to 2024. Commercial Channel revenue grew by 15% year over year to $48.4 million, while OEM Channel revenue saw a 17% decrease for the year, totaling $64.4 million. The company achieved a 57% gross margin for the year. Operating expenses were $74.9 million. GAAP loss from continuing operations was - $10.0 million, and adjusted net income from continuing operations was $1.6 million. Adjusted EBITDA for the full year was $5.3 million. Operating cash flow amounted to $11.2 million, and free cash flow was $4.4 million.

#### Operational Metrics

International OA Pain Management grew 28% in the fourth quarter and 12% for the full year 2025. Revenue from the Integrity™ Implant System more than doubled in 2025, reaching $6 million. Through the end of Q4 2025, Anika Therapeutics, Inc. funded $5.5 million of its $15 million share repurchase commitment, with $10.7 million funded to date and completion expected in Q2 2026. The company anticipates approximately $2.5 million in annualized adjusted EBITDA savings and $3.0 million in annualized stock-based compensation savings from actions initiated to reduce general and administrative expenses in the first half of 2026.

#### Fiscal 2026 Guidance

Anika Therapeutics, Inc. projects total company revenue for 2026 to be between $114 million and $122.5 million, representing a 1% to 9% year-over-year increase. Commercial Channel revenue is expected to be $53 million to $58 million, maintaining a 10% to 20% year-over-year growth. OEM Channel revenue is forecast to be $61 million to $64.5 million, remaining flat to modestly lower year over year, with Adjusted EBITDA as a percent of revenue targeted at 5% to 10%.

### Related Stocks

- [Anika Therapeutics, Inc. (ANIK.US)](https://longbridge.com/en/quote/ANIK.US.md)

## Related News & Research

- [Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ANIK Stock News](https://longbridge.com/en/news/281661869.md)
- [Anika Therapeutics Q4 revenue beats](https://longbridge.com/en/news/277038936.md)
- [Paradigm Reaches 50% Enrolment in Global Phase 3 Osteoarthritis Trial](https://longbridge.com/en/news/281082518.md)
- [Endeavour To Announce Its Q1 2026 Results On 30 April 2026 | EDVMF Stock News](https://longbridge.com/en/news/281490237.md)
- [Itaú Unibanco Files Q4 2025 Pillar 3 Risk and Capital Report With Strong Capital Ratios](https://longbridge.com/en/news/281508938.md)